Search
Apomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigationalApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. … [A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: APO-GO PEN 10 MG/ML, APO-GO (AMPOULE 10 MG/ML)Solenopsis richteri
go.drugbank.com/drugs/DB11026ApprovedWhen stung, the bites are characterized by sterile pustules that are surrounded by reddened swelling along with redness extending beyond. … It is extracted from the black imported fire ant which is native to South Amercia. The species has also been introduced in North Amercia.
Categories: Non-Standardized Insect Venom Allergenic ExtractFenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnIt is currently sold under the name FINTEPLA® by Zogenix INC.[L14522] … It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCaspofungin
go.drugbank.com/drugs/DB00520ApprovedInvestigationalCaspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. … It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Synonyms: (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-transLevorphanol
go.drugbank.com/drugs/DB00854ApprovedIt is nearly as effective orally as by injection.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic
Fluoroestradiol F-18
go.drugbank.com/drugs/DB15690ApprovedInvestigationalacross metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies. … [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna.
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalBy inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms. … [L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve
International brands: Kalymin NFlucytosine
go.drugbank.com/drugs/DB01099ApprovedInvestigationalA fluorinated cytosine analog that is used as an antifungal agent.
Benznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.